We usually hear about the use of Diprospan . That is why below we will tell you what it is, what it is for, what its contraindications are and all the relevant information about this drug.

Diprospan – what is it

Diprospan is a medicine intended for systemic use. It is a combination of betamethasone sodium phosphate and betamethasone dipropionate. Like all injectable brands of betamethasone, it is a corticosteroid anti-inflammatory. It works by reducing inflammation and swelling that put pressure on nerves and cause pain.

Diprospan – what is it for

It can be used for numerous indications, including joint injections, gouty arthritis, inflammatory skin lesions, and many other corticosteroid-responsive problems. It has a wide variety of side effects. The deterioration of the skin, as in his anecdote, is usually something that is only seen if it is used excessively, something that the health professional should have stopped before reaching this point. There are several brands, all prescription drugs that should only be used by a medical professional.

Prompt therapeutic activity is achieved by the soluble ester, betamethasone sodium phosphate, which is rapidly absorbed after injection. Sustained activity is provided by betamethasone dipropionate, which is only slightly soluble and becomes a slowly absorbed repository, controlling symptoms for a prolonged period. The small crystal size of betamethasone dipropionate allows the use of a fine gauge needle (up to 26 g) for intradermal and intralesional administration.

Diprospan is prescribed in the following cases:

  • Allergic diseases;
  • Diseases of the musculoskeletal system and soft tissues;
  • Dermatological diseases;
  • Primary or secondary insufficiency of the adrenal cortex;
  • Hemoblastosis;
  • Systemic connective tissue diseases.

Also, Diprospan is prescribed for the treatment of other diseases and pathological conditions that require systemic glucocorticosteroid therapy. It is indicated for the treatment of  chronic corticosteroid-responsive disorders , such as the following conditions:

Musculoskeletal and soft tissue conditions

Rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, radiculitis, coccydynia, torticollis, sciatica, lumbago, ganglion cyst, exostosis, fasciitis.

Allergic Conditions

Chronic bronchial asthma (including adjunct therapy for asthmatic status), hay fever, angioneurotic edema, allergic bronchitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness, insect bites.

Dermatological conditions

Atopic dermatitis (nummular eczema), neurodermatitis (lichen simplex circumscribed), lipoidic necrobiosis diabeticorum, alopecia areata, discoid lupus erythematosus, psoriasis, keloids, pemphigus, dermatitis herpetiformis, urticaria, severe lichen planus, hypertrophic acne, solar contact dermatitis.

Collagen diseases

Disseminated lupus erythematosus, scleroderma, dermatomyositis, polyarteritis nodosa.

Neoplastic diseases

For the palliative treatment of leukemias and lymphomas in adults; childhood acute leukemia.

Diprospan – composition

Each ml of DIPROSPAN Suspension contains 5 mg of betamethasone as dipropionate and 2 mg of betamethasone as sodium phosphate in a sterile buffered vehicle.

Diprospan is produced as a slightly viscous transparent yellow suspension in 1 ml glass ampoules. One ml of the drug contains 2.63 mg of betamethasone sodium phosphate, 6.43 mg of betamethasone dipropionate and auxiliary substances such as:

  • Water for injections;
  • Sodium Hydrophosphate Dihydrate;
  • Sodium chloride;
  • Benzyl Alcohol;
  • Polysorbate 80;
  • Disodium edetate;
  • Metilparahidroxibenzoato;
  • Carmellose sodium;
  • Propyl Parahydroxybenzoate;
  • Macrogol;
  • Hydrochloric acid.

Diprospan – Dosage and Administration

The suspension is administered by the intramuscular, periarticular, intraarticular, intradermal, intravesical, intramuscular or interstitial routes. The method of administration and the dosage regimen of Diprospan are established individually, depending on the severity of the disease, the indications and the patient’s response to treatment.

In cases of systemic use of the drug, the starting dose is 1-2 ml on average.

Diprospan – Contraindications

The use of diprospan is contraindicated in case of hypersensitivity to the active and auxiliary components included in its composition, as well as in the following cases:

  • Systemic mycoses;
  • Infectious arthritis;
  • An unstable joint;

With caution, the drug is prescribed for patients with cirrhosis of the liver, ulcerative colitis, hypothyroidism, diverticulitis, peptic ulcer and duodenal ulcer, osteoporosis, severe myasthenia gravis, renal failure, thrombocytopenic purpura, and arterial hypertension.

During pregnancy and during the lactation period, the use of the drug is permissible only in those cases where the expected effect of therapy significantly exceeds the possible risk to the development of the fetus or baby.

As with other corticosteroids, it is contraindicated in patients with systemic fungal infections, in patients hypersensitive to betamethasone dipropionate, betamethasone sodium phosphate, other corticosteroids or any component of this product.

Diprospan – Adverse reactions

Although the probability of negative reactions to DIPROSPAN has been low, the possible appearance of known side effects with the use of corticosteroids should be taken into account: fluid and electrolyte disorders, musculoskeletal, gastrointestinal, dermatological, neurological, endocrine, ophthalmic, metabolic and psychiatric.

Adverse reactions are related to both dose and duration of therapy. Adverse reactions related to parenteral corticosteroid therapy include: rare cases of blindness associated with intralesional therapy around the face and head; hyperpigmentation or hypopigmentation; subcutaneous and cutaneous atrophy; sterile abscess; post-injection flare (after intra-articular use); Charcot-like arthropathy.

Diprospan – Precausiones

It is not for intravenous or subcutaneous use. Dose adjustments may be necessary for remissions or exacerbations of the disease process, individual patient’s response to therapy, and patient exposure to stress, e.g. severe infection, surgery, or injury. After cessation of long-term or high-dose corticosteroid therapy, a follow-up of up to one year may be necessary.

Diprospan – Side Effects

  • Hypernatremia, increased body weight and potassium release, hypokalemic alkalosis, increased calcium excretion, lipomatosis, fluid retention in tissues and negative nitrogen balance (metabolism);
  • Chronic heart failure and increased blood pressure (cardiovascular system);
  • Posterior subcapsular cataract, blindness, increased intraocular pressure, exophthalmos and glaucoma (organ of the eye);
  • Digestive tract injuries, pancreatitis, hiccups and flatulence (digestive system);
  • Seizures, insomnia, dizziness, mood swings, headache, euphoria, depression, and personality disorders (central and peripheral nervous system).

Diprospan causes endocrine and musculoskeletal system side effects , namely:

  • Violation of the menstrual cycle, secondary adrenal insufficiency, Itenko-Cushing syndrome, steroid diabetes, delayed growth and sexual development in children, reduced tolerance to carbohydrates and intrauterine growth disorder;
  • Muscle weakness, joint instability, steroid myopathy, pathological tubular bone fractures, loss of muscle mass, tendon rupture, increased myasthenic symptoms, compression fracture of the spine, and osteoporosis.

In addition, Diprospan can cause dermatological, allergic and other reactions , namely:

  • Violation of wound healing, petechiae, atrophy and thinning of the skin, increased sweating, ecchymosis, dermatitis, propensity to develop pyoderma and candidiasis, steroid acne and stretch marks;
  • Anaphylactic reactions, angioedema, shock and arterial hypotension;

It should be informed from the doctors when giving the drug in immunosuppressive doses to avoid contact with measles or chickenpox. The use of the drug with active tuberculosis is only allowed in cases of fulminant or disseminated tuberculosis in combination with adequate antituberculous therapy.

Patients in the period of drug therapy should refrain from potentially dangerous activities that require increased attention and speed of psychomotor reactions.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *